{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### This is a Tutorial Notebook to get started with CTO as soon as possible, without any frills\n",
    "- We will be attempting to view gpt decisions of clinical trial documents\n",
    "- The Prompt can be seen in [get_llm_predictions.py](../llm_prediction_on_pubmed/get_llm_predictions.py)\n",
    "- Prequisites:\n",
    "    - pip install all requirements as in the requirements.txt\n",
    "    - Navigate to https://zenodo.org/doi/10.5281/zenodo.11535960 (this link always resolves to the latest version), and download the latest version of CTO! \n",
    "    I downloaded the v0.3 supplementary.zip, and unzipped it in the parent directory.\n",
    "        ```bash\n",
    "        wget https://zenodo.org/records/11608615/files/supplementary.zip -P ../\n",
    "        unzip ../supplementary.zip -d ../\n",
    "        ```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT02673125_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The trial investigated the effectiveness of MitoGrade in a prospective paired study.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Number of participants\",\n",
      "            \"value\": \"379\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"mtDNA quantity threshold\",\n",
      "            \"value\": \"above which implantation was never observed\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Percentage of non-implanting euploid embryos with abnormal mtDNA levels\",\n",
      "            \"value\": \"30%\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Presence of mutations in blastocysts with elevated mtDNA levels\",\n",
      "            \"value\": \"not seen\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What was the number of participants in the trial?\",\n",
      "            \"answer\": \"379\",\n",
      "            \"options\": [\n",
      "                \"100\",\n",
      "                \"200\",\n",
      "                \"300\",\n",
      "                \"379\",\n",
      "                \"400\"\n",
      "            ],\n",
      "            \"correct_option\": \"379\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the mtDNA quantity threshold above which implantation was never observed?\",\n",
      "            \"answer\": \"above which implantation was never observed\",\n",
      "            \"options\": [\n",
      "                \"below which implantation was never observed\",\n",
      "                \"above which implantation was always observed\",\n",
      "                \"above which implantation was sometimes observed\",\n",
      "                \"above which implantation was rarely observed\",\n",
      "                \"above which implantation was never observed\"\n",
      "            ],\n",
      "            \"correct_option\": \"above which implantation was never observed\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What percentage of non-implanting euploid embryos had abnormal mtDNA levels?\",\n",
      "            \"answer\": \"30%\",\n",
      "            \"options\": [\n",
      "                \"10%\",\n",
      "                \"20%\",\n",
      "                \"30%\",\n",
      "                \"40%\",\n",
      "                \"50%\"\n",
      "            ],\n",
      "            \"correct_option\": \"30%\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"Were mutations seen in blastocysts with elevated mtDNA levels?\",\n",
      "            \"answer\": \"not seen\",\n",
      "            \"options\": [\n",
      "                \"seen\",\n",
      "                \"not seen\",\n",
      "                \"sometimes seen\",\n",
      "                \"rarely seen\",\n",
      "                \"always seen\"\n",
      "            ],\n",
      "            \"correct_option\": \"not seen\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"success\",\n",
      "    \"outcome reasoning\": \"The trial investigated the effectiveness of MitoGrade and did not mention any negative outcomes or issues. Additionally, the trial had a large number of participants (379) and established a mtDNA quantity threshold above which implantation was never observed. These factors suggest a successful outcome.\"\n",
      "}\n",
      "NCT02304120_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The trial investigated the effects of postural specific sensorimotor training in patients with chronic non-specific low back pain. The study used a parallel, single-blinded, randomised controlled design with two groups receiving different interventions. The main outcomes measured were self-reported pain and functional status. Secondary analysis included postural control variables and proprioception. The trial registration number is NCT02304120.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Number of participants\",\n",
      "            \"value\": 22\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Duration of intervention sessions\",\n",
      "            \"value\": \"9 x 30 minutes\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Duration of added interventions\",\n",
      "            \"value\": \"15 minutes\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Main outcomes measured\",\n",
      "            \"value\": \"self-reported pain and functional status\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Secondary analysis variables\",\n",
      "            \"value\": \"postural control variables and proprioception\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Trial registration number\",\n",
      "            \"value\": \"NCT02304120\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What were the main outcomes measured in the trial?\",\n",
      "            \"answer\": \"self-reported pain and functional status\",\n",
      "            \"options\": [\n",
      "                \"blood pressure and heart rate\",\n",
      "                \"lung capacity and oxygen saturation\",\n",
      "                \"self-reported pain and functional status\",\n",
      "                \"blood glucose levels and cholesterol\",\n",
      "                \"body temperature and weight\"\n",
      "            ],\n",
      "            \"correct_option\": \"self-reported pain and functional status\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many participants were included in the trial?\",\n",
      "            \"answer\": \"22\",\n",
      "            \"options\": [\n",
      "                \"15\",\n",
      "                \"22\",\n",
      "                \"30\",\n",
      "                \"40\",\n",
      "                \"50\"\n",
      "            ],\n",
      "            \"correct_option\": \"22\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the duration of the intervention sessions in the trial?\",\n",
      "            \"answer\": \"9 x 30 minutes\",\n",
      "            \"options\": [\n",
      "                \"5 x 20 minutes\",\n",
      "                \"9 x 30 minutes\",\n",
      "                \"12 x 45 minutes\",\n",
      "                \"6 x 25 minutes\",\n",
      "                \"10 x 35 minutes\"\n",
      "            ],\n",
      "            \"correct_option\": \"9 x 30 minutes\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What type of variables were analyzed in the secondary analysis of the trial?\",\n",
      "            \"answer\": \"postural control variables and proprioception\",\n",
      "            \"options\": [\n",
      "                \"blood test results\",\n",
      "                \"brain activity patterns\",\n",
      "                \"postural control variables and proprioception\",\n",
      "                \"genetic markers\",\n",
      "                \"urine composition\"\n",
      "            ],\n",
      "            \"correct_option\": \"postural control variables and proprioception\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the trial registration number?\",\n",
      "            \"answer\": \"NCT02304120\",\n",
      "            \"options\": [\n",
      "                \"NCT01234567\",\n",
      "                \"NCT09876543\",\n",
      "                \"NCT11122233\",\n",
      "                \"NCT45678901\",\n",
      "                \"NCT02304120\"\n",
      "            ],\n",
      "            \"correct_option\": \"NCT02304120\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"fail\",\n",
      "    \"outcome reasoning\": \"The trial did not show statistically significant improvement in pain reduction or functional improvement despite a significant improvement in functional status after sensorimotor training. Therefore, the outcome is predicted to be a failure.\"\n",
      "}\n",
      "NCT01742442_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The clinical trial NCT01742442 aimed to investigate the prevalence and impact of age-related problems in elderly cancer patients through a prospective observational study.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Study Design\",\n",
      "            \"value\": \"Prospective Observational Study\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Number of Participants\",\n",
      "            \"value\": 307\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Age Range\",\n",
      "            \"value\": \"70 years and older\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Treatment Type\",\n",
      "            \"value\": \"Systemic treatment\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Primary Outcome Measures\",\n",
      "            \"value\": \"Physical function (PF) and global quality of life (QoL) scores\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Assessment Tools\",\n",
      "            \"value\": \"Modified geriatric assessment (mGA), EORTC Quality of Life Core Questionnaire-C30\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What was the study design of the clinical trial?\",\n",
      "            \"answer\": \"Prospective Observational Study\",\n",
      "            \"options\": [\n",
      "                \"Randomized Controlled Trial\",\n",
      "                \"Case-Control Study\",\n",
      "                \"Cohort Study\",\n",
      "                \"Cross-Sectional Study\",\n",
      "                \"Prospective Observational Study\"\n",
      "            ],\n",
      "            \"correct_option\": \"Prospective Observational Study\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many participants were included in the study?\",\n",
      "            \"answer\": \"307\",\n",
      "            \"options\": [\n",
      "                \"100\",\n",
      "                \"200\",\n",
      "                \"307\",\n",
      "                \"400\",\n",
      "                \"500\"\n",
      "            ],\n",
      "            \"correct_option\": \"307\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the age range of the participants?\",\n",
      "            \"answer\": \"70 years and older\",\n",
      "            \"options\": [\n",
      "                \"50 years and older\",\n",
      "                \"60 years and older\",\n",
      "                \"70 years and older\",\n",
      "                \"80 years and older\",\n",
      "                \"90 years and older\"\n",
      "            ],\n",
      "            \"correct_option\": \"70 years and older\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What type of treatment did the participants receive?\",\n",
      "            \"answer\": \"Systemic treatment\",\n",
      "            \"options\": [\n",
      "                \"Surgery\",\n",
      "                \"Radiation therapy\",\n",
      "                \"Chemotherapy\",\n",
      "                \"Immunotherapy\",\n",
      "                \"Systemic treatment\"\n",
      "            ],\n",
      "            \"correct_option\": \"Systemic treatment\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What were the primary outcome measures of the study?\",\n",
      "            \"answer\": \"Physical function (PF) and global quality of life (QoL) scores\",\n",
      "            \"options\": [\n",
      "                \"Survival rate\",\n",
      "                \"Tumor size reduction\",\n",
      "                \"Side effects of treatment\",\n",
      "                \"Physical function (PF) and global quality of life (QoL) scores\",\n",
      "                \"Disease progression\"\n",
      "            ],\n",
      "            \"correct_option\": \"Physical function (PF) and global quality of life (QoL) scores\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"unsure\",\n",
      "    \"outcome reasoning\": \"The abstract does not provide information about the trial outcome or any statistical tests conducted. Therefore, it is not possible to predict the trial outcome based on the given information.\"\n",
      "}\n",
      "NCT04674904_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The clinical trial NCT04674904 aimed to investigate the effects of dry needling on pain, range of motion, and function in patients with Upper Cross Syndrome.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"number of participants\",\n",
      "            \"value\": \"60\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"study design\",\n",
      "            \"value\": \"Randomized Controlled Trial\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"primary outcome measure\",\n",
      "            \"value\": \"pain intensity\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"secondary outcome measures\",\n",
      "            \"value\": \"range of motion, function\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What is the study design of the clinical trial?\",\n",
      "            \"answer\": \"Randomized Controlled Trial\",\n",
      "            \"options\": [\n",
      "                \"Observational Study\",\n",
      "                \"Case-Control Study\",\n",
      "                \"Cohort Study\",\n",
      "                \"Randomized Controlled Trial\",\n",
      "                \"Cross-Sectional Study\"\n",
      "            ],\n",
      "            \"correct_option\": \"Randomized Controlled Trial\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What is the primary outcome measure of the trial?\",\n",
      "            \"answer\": \"pain intensity\",\n",
      "            \"options\": [\n",
      "                \"range of motion\",\n",
      "                \"function\",\n",
      "                \"pain intensity\",\n",
      "                \"muscle strength\",\n",
      "                \"quality of life\"\n",
      "            ],\n",
      "            \"correct_option\": \"pain intensity\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What are the secondary outcome measures of the trial?\",\n",
      "            \"answer\": \"range of motion, function\",\n",
      "            \"options\": [\n",
      "                \"pain intensity\",\n",
      "                \"muscle strength\",\n",
      "                \"quality of life\",\n",
      "                \"range of motion, function\",\n",
      "                \"adverse events\"\n",
      "            ],\n",
      "            \"correct_option\": \"range of motion, function\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many participants were involved in the trial?\",\n",
      "            \"answer\": \"60\",\n",
      "            \"options\": [\n",
      "                \"30\",\n",
      "                \"45\",\n",
      "                \"60\",\n",
      "                \"75\",\n",
      "                \"90\"\n",
      "            ],\n",
      "            \"correct_option\": \"60\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"unsure\",\n",
      "    \"outcome reasoning\": \"The outcome of the trial cannot be determined without information about the statistical tests and results. The abstracts do not provide this information.\"\n",
      "}\n",
      "NCT02646813_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The clinical trial NCT02646813 aims to compare the intraluminal and extraluminal placement of the Arndt bronchial blockers for adult thoracic surgery. The trial investigates the efficacy and safety of these two placement techniques.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Study Design\",\n",
      "            \"value\": \"Randomized Controlled Trial\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Number of Participants\",\n",
      "            \"value\": \"60\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Primary Outcome Measure\",\n",
      "            \"value\": \"Success rate of bronchial blocker placement\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Secondary Outcome Measures\",\n",
      "            \"value\": \"Complications, time required for placement, ease of placement\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What is the study design of the clinical trial?\",\n",
      "            \"answer\": \"Randomized Controlled Trial\",\n",
      "            \"options\": [\n",
      "                \"Observational Study\",\n",
      "                \"Case-Control Study\",\n",
      "                \"Cohort Study\",\n",
      "                \"Randomized Controlled Trial\",\n",
      "                \"Cross-Sectional Study\"\n",
      "            ],\n",
      "            \"correct_option\": \"Randomized Controlled Trial\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many participants are included in the trial?\",\n",
      "            \"answer\": \"60\",\n",
      "            \"options\": [\n",
      "                \"30\",\n",
      "                \"45\",\n",
      "                \"60\",\n",
      "                \"75\",\n",
      "                \"90\"\n",
      "            ],\n",
      "            \"correct_option\": \"60\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What is the primary outcome measure of the trial?\",\n",
      "            \"answer\": \"Success rate of bronchial blocker placement\",\n",
      "            \"options\": [\n",
      "                \"Complications\",\n",
      "                \"Time required for placement\",\n",
      "                \"Ease of placement\",\n",
      "                \"Success rate of bronchial blocker placement\",\n",
      "                \"Patient satisfaction\"\n",
      "            ],\n",
      "            \"correct_option\": \"Success rate of bronchial blocker placement\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What are the secondary outcome measures of the trial?\",\n",
      "            \"answer\": \"Complications, time required for placement, ease of placement\",\n",
      "            \"options\": [\n",
      "                \"Complications, time required for placement, ease of placement\",\n",
      "                \"Success rate of bronchial blocker placement, patient satisfaction\",\n",
      "                \"Complications, patient satisfaction, ease of placement\",\n",
      "                \"Time required for placement, patient satisfaction, ease of placement\",\n",
      "                \"Success rate of bronchial blocker placement, time required for placement\"\n",
      "            ],\n",
      "            \"correct_option\": \"Complications, time required for placement, ease of placement\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"unsure\",\n",
      "    \"outcome reasoning\": \"The outcome of the trial cannot be determined without the primary outcome measure results and statistical analysis. Further information is needed to predict the outcome.\"\n",
      "}\n",
      "NCT01536587_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The trial evaluated the effects of inhaled therapy with salmeterol on muscle sympathetic nerve activity (MSNA) in COPD patients. It found that salmeterol did not significantly change MSNA despite reducing hyperinflation. Heart rate increased significantly after salmeterol treatment.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Change in MSNA following acute administration of salmeterol vs. placebo\",\n",
      "            \"value\": \"-1.96 +/- 9.81 vs. -0.65 +/- 9.07; p = 0.51\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Change in heart rate after 4 weeks of salmeterol treatment\",\n",
      "            \"value\": \"3.9 +/- 4.3 bpm\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What was the change in MSNA following acute administration of salmeterol compared to placebo?\",\n",
      "            \"answer\": \"No significant difference\",\n",
      "            \"options\": [\n",
      "                \"Decreased significantly\",\n",
      "                \"Increased significantly\",\n",
      "                \"No significant difference\",\n",
      "                \"Not mentioned\",\n",
      "                \"Varied among patients\"\n",
      "            ],\n",
      "            \"correct_option\": \"No significant difference\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"Did heart rate increase or decrease after 4 weeks of salmeterol treatment?\",\n",
      "            \"answer\": \"Increased\",\n",
      "            \"options\": [\n",
      "                \"Increased\",\n",
      "                \"Decreased\",\n",
      "                \"Remained the same\",\n",
      "                \"Not mentioned\",\n",
      "                \"Varied among patients\"\n",
      "            ],\n",
      "            \"correct_option\": \"Increased\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"unsure\",\n",
      "    \"outcome reasoning\": \"The trial did not report a clear primary outcome or statistical significance. The change in MSNA following salmeterol was not significant, and the increase in heart rate may not be clinically significant. Therefore, the outcome is uncertain.\"\n",
      "}\n",
      "NCT05362656_gpt_response.json\n",
      "{\n",
      "    \"description\": \"This trial aimed to evaluate the Artificial Intelligence Software VX1+ for detecting and tagging spatio-temporal dispersion areas during atrial fibrillation or atrial tachycardia ablation procedures.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"number of participants\",\n",
      "            \"value\": 30\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"study design\",\n",
      "            \"value\": \"clinical trial\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"primary outcome measure\",\n",
      "            \"value\": \"accuracy of the software in detecting and tagging spatio-temporal dispersion areas\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What was the primary focus of the trial?\",\n",
      "            \"answer\": \"To evaluate the Artificial Intelligence Software VX1+ for detecting and tagging spatio-temporal dispersion areas during atrial fibrillation or atrial tachycardia ablation procedures.\",\n",
      "            \"options\": [\n",
      "                \"To study the effects of medication on heart rate\",\n",
      "                \"To evaluate the impact of diet on blood pressure\",\n",
      "                \"To assess the effectiveness of a new surgical technique for knee replacement\",\n",
      "                \"To investigate the relationship between exercise and cholesterol levels\",\n",
      "                \"To evaluate the software for detecting and tagging spatio-temporal dispersion areas during ablation procedures\"\n",
      "            ],\n",
      "            \"correct_option\": \"To evaluate the software for detecting and tagging spatio-temporal dispersion areas during ablation procedures\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the study design of the trial?\",\n",
      "            \"answer\": \"Clinical trial\",\n",
      "            \"options\": [\n",
      "                \"Observational study\",\n",
      "                \"Meta-analysis\",\n",
      "                \"Case-control study\",\n",
      "                \"Clinical trial\",\n",
      "                \"Cross-sectional study\"\n",
      "            ],\n",
      "            \"correct_option\": \"Clinical trial\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many participants were involved in the trial?\",\n",
      "            \"answer\": \"30\",\n",
      "            \"options\": [\n",
      "                \"20\",\n",
      "                \"30\",\n",
      "                \"40\",\n",
      "                \"50\",\n",
      "                \"60\"\n",
      "            ],\n",
      "            \"correct_option\": \"30\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"unsure\",\n",
      "    \"outcome reasoning\": \"The outcome of the trial cannot be definitively predicted based on the provided information. Further details on the results and statistical analysis would be needed to determine the success or failure of the trial.\"\n",
      "}\n",
      "NCT00346944_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The clinical trial NCT00346944 aimed to study the health effects of removing amalgam restorations in patients with symptoms allegedly related to dental amalgam. The trial examined patients at the Dental Biomaterials Adverse Reaction Unit from 1993 to 1999. The study characterized the changes in health complaints before and after removal of amalgam fillings and compared them with an external reference group from the general population. The study found that the intensity of health complaints was higher in the treatment group before removal of amalgam fillings compared to the reference group. After a 3-year follow-up, there was a significant reduction in the intensity of various health complaints, including taste disturbances, pain from muscles and joints, gastrointestinal complaints, complaints from ear/nose/throat, and fatigue. The reduction in health complaints varied among individuals, and multiple factors may have contributed to the observed reduction.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Number of participants\",\n",
      "            \"value\": \"20\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Duration of follow-up\",\n",
      "            \"value\": \"3 years\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Health complaints before treatment\",\n",
      "            \"value\": \"Higher intensity in the treatment group compared to the reference group\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Health complaints after a 3-year follow-up\",\n",
      "            \"value\": \"Reduction in taste disturbances, pain from muscles and joints, gastrointestinal complaints, complaints from ear/nose/throat, and fatigue\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What was the duration of the follow-up period?\",\n",
      "            \"answer\": \"3 years\",\n",
      "            \"options\": [\n",
      "                \"1 month\",\n",
      "                \"6 months\",\n",
      "                \"1 year\",\n",
      "                \"2 years\",\n",
      "                \"3 years\"\n",
      "            ],\n",
      "            \"correct_option\": \"3 years\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many participants were included in the study?\",\n",
      "            \"answer\": \"20\",\n",
      "            \"options\": [\n",
      "                \"10\",\n",
      "                \"15\",\n",
      "                \"20\",\n",
      "                \"25\",\n",
      "                \"30\"\n",
      "            ],\n",
      "            \"correct_option\": \"20\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the main finding of the study?\",\n",
      "            \"answer\": \"Reduction in taste disturbances, pain from muscles and joints, gastrointestinal complaints, complaints from ear/nose/throat, and fatigue\",\n",
      "            \"options\": [\n",
      "                \"Increase in health complaints\",\n",
      "                \"No change in health complaints\",\n",
      "                \"Reduction in taste disturbances\",\n",
      "                \"Reduction in gastrointestinal complaints\",\n",
      "                \"Reduction in fatigue\"\n",
      "            ],\n",
      "            \"correct_option\": \"Reduction in taste disturbances, pain from muscles and joints, gastrointestinal complaints, complaints from ear/nose/throat, and fatigue\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How did the intensity of health complaints in the treatment group compare to the reference group before treatment?\",\n",
      "            \"answer\": \"Higher intensity in the treatment group compared to the reference group\",\n",
      "            \"options\": [\n",
      "                \"Higher intensity in the reference group compared to the treatment group\",\n",
      "                \"No difference in intensity between the treatment and reference groups\",\n",
      "                \"Lower intensity in the treatment group compared to the reference group\",\n",
      "                \"Equal intensity in the treatment and reference groups\",\n",
      "                \"Cannot be determined\"\n",
      "            ],\n",
      "            \"correct_option\": \"Higher intensity in the treatment group compared to the reference group\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the aim of the clinical trial?\",\n",
      "            \"answer\": \"To study the health effects of removing amalgam restorations in patients with symptoms allegedly related to dental amalgam\",\n",
      "            \"options\": [\n",
      "                \"To compare different restorative materials\",\n",
      "                \"To study the health effects of dental amalgam\",\n",
      "                \"To study the health effects of dental biomaterials\",\n",
      "                \"To study the health effects of dental fillings\",\n",
      "                \"To study the health effects of dental procedures\"\n",
      "            ],\n",
      "            \"correct_option\": \"To study the health effects of removing amalgam restorations in patients with symptoms allegedly related to dental amalgam\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"success\",\n",
      "    \"outcome reasoning\": \"The trial found a significant reduction in the intensity of various health complaints after a 3-year follow-up. This suggests that the removal of amalgam fillings had a positive effect on the patients' health. Additionally, the trial compared the health complaints of the treatment group with an external reference group and found that the intensity of complaints was higher in the treatment group before treatment. Based on these findings, it can be inferred that the trial outcome is likely to be successful.\"\n",
      "}\n",
      "NCT04320173_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The lidocaine topical system 1.8% demonstrated superior adhesion performance compared to lidocaine patch 5%, lidocaine medicated plaster 5%, and generic lidocaine patch 5% in healthy human subjects.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Number of participants\",\n",
      "            \"value\": \"125\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Adhesion performance of lidocaine topical system 1.8%\",\n",
      "            \"value\": \">/=90% adhesion throughout the 12-hour administration period\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Adhesion performance of lidocaine patch 5%\",\n",
      "            \"value\": \"13.6% subjects demonstrated >/=90% adhesion\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Adhesion performance of lidocaine medicated plaster 5%\",\n",
      "            \"value\": \"15.9% subjects demonstrated >/=90% adhesion\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Adhesion performance of generic lidocaine patch 5%\",\n",
      "            \"value\": \"0% subjects demonstrated >/=90% adhesion\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What was the primary objective of the study?\",\n",
      "            \"answer\": \"To evaluate adhesion performance of the lidocaine topical system 1.8%\",\n",
      "            \"options\": [\n",
      "                \"To assess skin irritation in healthy human subjects\",\n",
      "                \"To compare different lidocaine products in unhealthy subjects\",\n",
      "                \"To evaluate the efficacy of lidocaine patch 5%\",\n",
      "                \"To study the impact of lidocaine on pain management\",\n",
      "                \"To analyze the cost-effectiveness of lidocaine products\"\n",
      "            ],\n",
      "            \"correct_option\": \"To evaluate adhesion performance of the lidocaine topical system 1.8%\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What percentage of subjects treated with lidocaine topical system 1.8% demonstrated >/=90% adhesion throughout the 12-hour administration period?\",\n",
      "            \"answer\": \">/=90% adhesion throughout the 12-hour administration period\",\n",
      "            \"options\": [\n",
      "                \"10%\",\n",
      "                \"25%\",\n",
      "                \"50%\",\n",
      "                \"75%\",\n",
      "                \"90%\"\n",
      "            ],\n",
      "            \"correct_option\": \">/=90% adhesion throughout the 12-hour administration period\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What percentage of subjects treated with generic lidocaine patch 5% demonstrated >/=90% adhesion throughout the 12-hour administration period?\",\n",
      "            \"answer\": \"0% subjects demonstrated >/=90% adhesion\",\n",
      "            \"options\": [\n",
      "                \"10%\",\n",
      "                \"25%\",\n",
      "                \"50%\",\n",
      "                \"75%\",\n",
      "                \"0%\"\n",
      "            ],\n",
      "            \"correct_option\": \"0% subjects demonstrated >/=90% adhesion\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was observed in terms of skin irritation across the different lidocaine topical products?\",\n",
      "            \"answer\": \"Minimal skin irritation was observed\",\n",
      "            \"options\": [\n",
      "                \"Severe skin irritation was observed\",\n",
      "                \"No skin irritation was observed\",\n",
      "                \"Moderate skin irritation was observed\",\n",
      "                \"Significant skin irritation was observed\",\n",
      "                \"Minimal skin irritation was observed\"\n",
      "            ],\n",
      "            \"correct_option\": \"Minimal skin irritation was observed\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"How many Phase 1 adhesion performance studies were conducted in healthy adult volunteers?\",\n",
      "            \"answer\": \"Three studies\",\n",
      "            \"options\": [\n",
      "                \"One study\",\n",
      "                \"Two studies\",\n",
      "                \"Three studies\",\n",
      "                \"Four studies\",\n",
      "                \"Five studies\"\n",
      "            ],\n",
      "            \"correct_option\": \"Three studies\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"success\",\n",
      "    \"outcome reasoning\": \"The lidocaine topical system 1.8% demonstrated superior adhesion performance compared to other lidocaine products, and minimal skin irritation was observed. The primary objective was successfully achieved, indicating a successful outcome.\"\n",
      "}\n",
      "NCT01203358_gpt_response.json\n",
      "{\n",
      "    \"description\": \"The trial compared the efficacy of Exosurf Neonatal and Survanta for the treatment of neonatal respiratory distress syndrome. The main outcome measures were the occurrence of death or bronchopulmonary dysplasia 28 days after birth, average fraction of inspired oxygen (FIO2), and mean airway pressure (MAP) during the first 72 hours after treatment.\",\n",
      "    \"extracted features\": [\n",
      "        {\n",
      "            \"description\": \"Occurrence of death or bronchopulmonary dysplasia\",\n",
      "            \"value\": \"67% for Exosurf, 62% for Survanta\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Average FIO2 during the first 72 hours after treatment\",\n",
      "            \"value\": \"0.50 +/- 0.01 for Exosurf, 0.42 +/- 0.01 for Survanta\"\n",
      "        },\n",
      "        {\n",
      "            \"description\": \"Average MAP during the first 72 hours after treatment\",\n",
      "            \"value\": \"7.64 +/- 0.21 cm H2O for Exosurf, 6.93 +/- 0.21 cm H2O for Survanta\"\n",
      "        }\n",
      "    ],\n",
      "    \"questions\": [\n",
      "        {\n",
      "            \"question\": \"What were the main outcome measures of the trial?\",\n",
      "            \"answer\": \"The main outcome measures were the occurrence of death or bronchopulmonary dysplasia 28 days after birth, average fraction of inspired oxygen (FIO2), and mean airway pressure (MAP) during the first 72 hours after treatment.\",\n",
      "            \"options\": [\n",
      "                \"Comparison of different surfactant brands\",\n",
      "                \"Duration of hospitalization\",\n",
      "                \"Incidence of other neonatal morbidities\",\n",
      "                \"Average body temperature\",\n",
      "                \"Average heart rate\"\n",
      "            ],\n",
      "            \"correct_option\": \"The main outcome measures were the occurrence of death or bronchopulmonary dysplasia 28 days after birth, average fraction of inspired oxygen (FIO2), and mean airway pressure (MAP) during the first 72 hours after treatment.\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the occurrence of death or bronchopulmonary dysplasia in the Exosurf group?\",\n",
      "            \"answer\": \"67%\",\n",
      "            \"options\": [\n",
      "                \"62%\",\n",
      "                \"70%\",\n",
      "                \"55%\",\n",
      "                \"75%\",\n",
      "                \"80%\"\n",
      "            ],\n",
      "            \"correct_option\": \"67%\"\n",
      "        },\n",
      "        {\n",
      "            \"question\": \"What was the average FIO2 during the first 72 hours after treatment for Survanta?\",\n",
      "            \"answer\": \"0.42 +/- 0.01\",\n",
      "            \"options\": [\n",
      "                \"0.50 +/- 0.01\",\n",
      "                \"0.40 +/- 0.01\",\n",
      "                \"0.45 +/- 0.01\",\n",
      "                \"0.55 +/- 0.01\",\n",
      "                \"0.60 +/- 0.01\"\n",
      "            ],\n",
      "            \"correct_option\": \"0.42 +/- 0.01\"\n",
      "        }\n",
      "    ],\n",
      "    \"outcome\": \"unsure\",\n",
      "    \"outcome reasoning\": \"The trial did not show a significant difference in the incidence of death or bronchopulmonary dysplasia between the Exosurf and Survanta groups. However, there was a difference in the initial response to treatment as measured by FIO2 and MAP. Further analysis may be needed to determine the overall outcome of the trial.\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import numpy as np\n",
    "import json\n",
    "files = os.listdir('../supplementary/llm_prediction_on_pubmed/gpt-35-decisions/')\n",
    "\n",
    "# randomly select 10 files\n",
    "np.random.seed(0)\n",
    "inds = np.random.choice(len(files), 10, replace=False)\n",
    "for i in inds:\n",
    "    print(files[i])\n",
    "    with open('../supplementary/llm_prediction_on_pubmed/gpt-35-decisions/' + files[i], 'r') as f:\n",
    "        json_dict = json.loads(f.read())\n",
    "    print(json.dumps(json_dict, indent=4))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "dp",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
